General
Preferred name
Venglustat
Synonyms
SAR402671 ()
GZ402671 ()
Ibiglustat L-Malic acid ()
GZ402671 (L-Malic acid) ()
Venglustat (L-Malic acid) ()
SAR402671 (L-Malic acid) ()
Ibiglustat ()
Genz 682452 ()
GZ-402671 ()
Ibiglustat (L-Malic acid) ()
Ibiglustat (succinate) ()
Venglustat (succinate) ()
SAR402671 (succinate) ()
GZ402671 (succinate) ()
VENGLUSTAT MALATE ()
Genz-682452 ()
Gz402671 ()
Genz-682452-AA ()
SAR-402671 ()
GZ/SAR-402671 ()
Gz/sar402671 ()
Ibiglustat l-malate ()
Venglustat l-malate ()
GZ/SAR-402671A ()
GZ/SAR402671A ()
SAR-402671A ()
SAR402671A ()
Genz-682452-AU ()
P&D ID
PD098979
CAS
1401090-53-6
1629063-78-0
1629063-80-4
Tags
available
drug candidate
Drug indication
Gaucher disease type 1
Gaucher disease
Autosomal dominant polycystic kidney disease
Fabry disease
Parkinson disease
Drug Status
investigational
Max Phase
2.0
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Venglustat is a clinical stage oral glucosylceramide synthase (GCS) inhibitor. GCS is encoded by the UGCG gene. It was developed for potential to treat diseases in which the glycolipid glucosylceramide accumulates and leads to lysosomal dysfunction and organ damage . Venglustat inhibits glucosylceramide synthesis. Its chemical structure is claimed in Genzyme's patent WO2012129084A2 . It has subsequently been reported to act as a substrate-competitive inhibitor of N-terminal Xaa-Pro-Lys N-methyltransferase 1 (NTMT1; Q9BV86; IC50 420 nM) .

The venglustat analogue GENZ-667161 and the analogue GENZ-123346 have been shown to inhibit replication of SARS-CoV-2 in vitro , potentially by disrupting the host cell membrane dynamics which the virions depend upon for infection. (GtoPdb)
DESCRIPTION Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
PRICE 142
DESCRIPTION Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
PRICE 233
DESCRIPTION Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
DESCRIPTION Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body. (TargetMol Bioactive Compound Library)
DESCRIPTION Ibiglustat (L-Malic acid) (Ibiglustat L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson's disease, SRT in Fabry's and Gaucher's. (TargetMol Bioactive Compound Library)
Compound Sets
12
AdooQ Bioactive Compound Library
A21083
Cayman Chemical Bioactives
32878
ChEMBL Drugs
CHEMBL4297611
CHEMBL4594270
Drug Repurposing Hub
DrugBank
DB14966
DrugMAP
DMLPEZS
Guide to Pharmacology
11550
Mcule NIBR MoA Box Subset
MCULE-9787774989
MedChem Express Bioactive Compound Library
HY-16743
HY-16743A
HY-16743B
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
T4473
T11599
External IDs
39
Properties
(calculated by RDKit )
Molecular Weight
389.16
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
2
cLogP
4.0
TPSA
54.46
Fraction CSP3
0.5
Chiral centers
1.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
glucosylceramide synthase
Glucosylceramide Synthase (GCS)
MOA
Transferase inhibitor
Glucosylceramidase inhibitor
Member status
member
Pathway
Metabolism
Neuronal Signaling
Source data